Cargando…
Split‐dose 1 L polyethylene glycol (PEG) with ascorbate is non‐inferior to split‐dose PEG with sodium picosulfate and magnesium citrate with similar tolerability: a randomized study
BACKGROUND AND AIM: Post‐marketing studies comparing low‐volume polyethylene glycol (PEG)‐based regimens are limited. This randomized study aimed to compare the efficacy and tolerability of a novel 1‐L low‐volume PEG‐based preparation: 1 L PEG+Asc (PEG3350, sodium ascorbate, sodium sulfate, ascorbic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454467/ https://www.ncbi.nlm.nih.gov/pubmed/34584971 http://dx.doi.org/10.1002/jgh3.12626 |
_version_ | 1784570498057764864 |
---|---|
author | Nalankilli, Kumanan Gibson, David J Anwar, Shahzaib Con, Danny Chen, Helen Secomb, Robyn Gibson, Peter Brown, Gregor |
author_facet | Nalankilli, Kumanan Gibson, David J Anwar, Shahzaib Con, Danny Chen, Helen Secomb, Robyn Gibson, Peter Brown, Gregor |
author_sort | Nalankilli, Kumanan |
collection | PubMed |
description | BACKGROUND AND AIM: Post‐marketing studies comparing low‐volume polyethylene glycol (PEG)‐based regimens are limited. This randomized study aimed to compare the efficacy and tolerability of a novel 1‐L low‐volume PEG‐based preparation: 1 L PEG+Asc (PEG3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride) with PEG+SPMC (PEG3350, sodium chloride, potassium chloride and sodium sulfate, sodium picosulfate, magnesium oxide, citric acid, and aspartame), prior to routine colonoscopy at an Australian tertiary referral center. METHODS: Outpatients undergoing colonoscopy were randomized to receive either split‐dose 1 L PEG+Asc or split‐dose PEG+SPMC. Bowel preparation quality using the Boston Bowel Preparation Scale (BPPS), modified Aronchick scores, procedure time, cecal intubation, and adenoma detection rates were recorded. Patient compliance and tolerability were captured using a standardized questionnaire. RESULTS: A total of 173 patients were randomized, of whom 164 completed the study and were allocated to 1 L PEG+Asc (n = 82) or PEG+SPMC (n = 82). Non‐inferiority of 1 L PEG+Asc was demonstrated with 89% achieving successful preparation (total BPPS ≥6 and each sub‐score ≥2) compared with 85.4% in the PEG+SPMC group, resulting in an estimated difference of 3.7% (95% CI −6.6% to 13.9%). The median BBPS was non‐inferior in all colonic segments with 1 L PEG+Asc (BBPS 3 [interquartile range 2–3]) vs PEG+SPMC (BBPS 2 [interquartile range 2–3]). More 1 L PEG+Asc patients reported moderate to severe nausea (P = 0.028), but overall tolerability was similar. CONCLUSIONS: The quality of bowel preparation achieved with 1 L PEG+Asc is non‐inferior to that with PEG+SPMC, with similar tolerability outcomes. Further studies are required in patients at risk of suboptimal bowel preparation. |
format | Online Article Text |
id | pubmed-8454467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wiley Publishing Asia Pty Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-84544672021-09-27 Split‐dose 1 L polyethylene glycol (PEG) with ascorbate is non‐inferior to split‐dose PEG with sodium picosulfate and magnesium citrate with similar tolerability: a randomized study Nalankilli, Kumanan Gibson, David J Anwar, Shahzaib Con, Danny Chen, Helen Secomb, Robyn Gibson, Peter Brown, Gregor JGH Open Original Articles BACKGROUND AND AIM: Post‐marketing studies comparing low‐volume polyethylene glycol (PEG)‐based regimens are limited. This randomized study aimed to compare the efficacy and tolerability of a novel 1‐L low‐volume PEG‐based preparation: 1 L PEG+Asc (PEG3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride) with PEG+SPMC (PEG3350, sodium chloride, potassium chloride and sodium sulfate, sodium picosulfate, magnesium oxide, citric acid, and aspartame), prior to routine colonoscopy at an Australian tertiary referral center. METHODS: Outpatients undergoing colonoscopy were randomized to receive either split‐dose 1 L PEG+Asc or split‐dose PEG+SPMC. Bowel preparation quality using the Boston Bowel Preparation Scale (BPPS), modified Aronchick scores, procedure time, cecal intubation, and adenoma detection rates were recorded. Patient compliance and tolerability were captured using a standardized questionnaire. RESULTS: A total of 173 patients were randomized, of whom 164 completed the study and were allocated to 1 L PEG+Asc (n = 82) or PEG+SPMC (n = 82). Non‐inferiority of 1 L PEG+Asc was demonstrated with 89% achieving successful preparation (total BPPS ≥6 and each sub‐score ≥2) compared with 85.4% in the PEG+SPMC group, resulting in an estimated difference of 3.7% (95% CI −6.6% to 13.9%). The median BBPS was non‐inferior in all colonic segments with 1 L PEG+Asc (BBPS 3 [interquartile range 2–3]) vs PEG+SPMC (BBPS 2 [interquartile range 2–3]). More 1 L PEG+Asc patients reported moderate to severe nausea (P = 0.028), but overall tolerability was similar. CONCLUSIONS: The quality of bowel preparation achieved with 1 L PEG+Asc is non‐inferior to that with PEG+SPMC, with similar tolerability outcomes. Further studies are required in patients at risk of suboptimal bowel preparation. Wiley Publishing Asia Pty Ltd 2021-08-17 /pmc/articles/PMC8454467/ /pubmed/34584971 http://dx.doi.org/10.1002/jgh3.12626 Text en © 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Nalankilli, Kumanan Gibson, David J Anwar, Shahzaib Con, Danny Chen, Helen Secomb, Robyn Gibson, Peter Brown, Gregor Split‐dose 1 L polyethylene glycol (PEG) with ascorbate is non‐inferior to split‐dose PEG with sodium picosulfate and magnesium citrate with similar tolerability: a randomized study |
title | Split‐dose 1 L polyethylene glycol (PEG) with ascorbate is non‐inferior to split‐dose PEG with sodium picosulfate and magnesium citrate with similar tolerability: a randomized study |
title_full | Split‐dose 1 L polyethylene glycol (PEG) with ascorbate is non‐inferior to split‐dose PEG with sodium picosulfate and magnesium citrate with similar tolerability: a randomized study |
title_fullStr | Split‐dose 1 L polyethylene glycol (PEG) with ascorbate is non‐inferior to split‐dose PEG with sodium picosulfate and magnesium citrate with similar tolerability: a randomized study |
title_full_unstemmed | Split‐dose 1 L polyethylene glycol (PEG) with ascorbate is non‐inferior to split‐dose PEG with sodium picosulfate and magnesium citrate with similar tolerability: a randomized study |
title_short | Split‐dose 1 L polyethylene glycol (PEG) with ascorbate is non‐inferior to split‐dose PEG with sodium picosulfate and magnesium citrate with similar tolerability: a randomized study |
title_sort | split‐dose 1 l polyethylene glycol (peg) with ascorbate is non‐inferior to split‐dose peg with sodium picosulfate and magnesium citrate with similar tolerability: a randomized study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454467/ https://www.ncbi.nlm.nih.gov/pubmed/34584971 http://dx.doi.org/10.1002/jgh3.12626 |
work_keys_str_mv | AT nalankillikumanan splitdose1lpolyethyleneglycolpegwithascorbateisnoninferiortosplitdosepegwithsodiumpicosulfateandmagnesiumcitratewithsimilartolerabilityarandomizedstudy AT gibsondavidj splitdose1lpolyethyleneglycolpegwithascorbateisnoninferiortosplitdosepegwithsodiumpicosulfateandmagnesiumcitratewithsimilartolerabilityarandomizedstudy AT anwarshahzaib splitdose1lpolyethyleneglycolpegwithascorbateisnoninferiortosplitdosepegwithsodiumpicosulfateandmagnesiumcitratewithsimilartolerabilityarandomizedstudy AT condanny splitdose1lpolyethyleneglycolpegwithascorbateisnoninferiortosplitdosepegwithsodiumpicosulfateandmagnesiumcitratewithsimilartolerabilityarandomizedstudy AT chenhelen splitdose1lpolyethyleneglycolpegwithascorbateisnoninferiortosplitdosepegwithsodiumpicosulfateandmagnesiumcitratewithsimilartolerabilityarandomizedstudy AT secombrobyn splitdose1lpolyethyleneglycolpegwithascorbateisnoninferiortosplitdosepegwithsodiumpicosulfateandmagnesiumcitratewithsimilartolerabilityarandomizedstudy AT gibsonpeter splitdose1lpolyethyleneglycolpegwithascorbateisnoninferiortosplitdosepegwithsodiumpicosulfateandmagnesiumcitratewithsimilartolerabilityarandomizedstudy AT browngregor splitdose1lpolyethyleneglycolpegwithascorbateisnoninferiortosplitdosepegwithsodiumpicosulfateandmagnesiumcitratewithsimilartolerabilityarandomizedstudy |